- This topic has 2 replies, 2 voices, and was last updated 3 years, 7 months ago by
.
-
Posts
-
-
Ella Balasa, a columnist at CF News Today, was recently granted early access to the “triple combo” — the latest CFTR modulator therapy from Vertex, which is currently being evaluated by the FDA.
Here’s what Ella has to say about it:
“I started the triple combo on September 23rd at 25% lung function. I have been followed at Duke for transplant, but have wanted to hold off on being listed until I gave the triple a shot. After starting, I caught what I thought to be a cold and had increased mucus and sinus draining for about 2 weeks, then it started to reduce in volume.
I use 3 liters of oxygen when exercising, and my O2 needs have been about the same so I didn’t expect much improvement after 3 weeks. But I had PFTs done and they increased 4% up to 29%! I was shocked, but so happy! I hope to continue seeing improvement as I know I still have mucus plugs in my lungs.”
Follow Ella’s journey on Instagram at: https://www.instagram.com/thisgirlella/
What are your hopes and expectations for the triple combo?
-
-
-
- You must be logged in to reply to this topic.
